| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Impact of two-session fecal microbiota transplantation on minimal hepatic encephalopathy in cirrhosis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ankit Agarwal, Samagra Agrawal, Daizee Talukdar, Manjeet Kaur, Sagnik Biswas, Shekhar Swaroop, Rithvik Golla, Bharti Kandiyal, Pradip Jana, Subhash Tanwar, Arnav Aggarwal, Hem C Singh, Ayush Agarwal, Mridul Mahajan, Bipin Tiwari, Baibaswata Nayak, Amit Goel, Bhabatosh Das and Shalimar |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Department of Biotechnology (DBT), Govt. of India |
No. BT/PR30159/MED/15/188/2018 |
| Science and Engineering Research Board |
No. SPR/2020/00315 |
| Blockchain For Impact |
No. 2025 |
|
| Corresponding Author |
Shalimar, Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, Delhi, India. drshalimar@gmail.com |
| Key Words |
Minimal hepatic encephalopathy; Fecal microbiota transplantation; Probiotics; Lactulose; Bacteria |
| Core Tip |
Minimal hepatic encephalopathy (MHE) is common in cirrhosis. Gut dysbiosis is a key pathogenic player of MHE. Lactulose has been demonstrated to reverse MHE and prevent progression to overt HE. This randomised trial compared two endoscopic fecal microbiota transplantations (1 month apart) with daily lactulose over 3 months for MHE reversal. We found fecal microbiota transplantation and lactulose to have similar efficacy in improving MHE, supporting microbiota-targeted therapy as a viable alternative to standard care for MHE. These findings justify larger trials to assess long-term outcomes and optimal microbiota-based strategies. |
| Publish Date |
2026-04-21 08:57 |
| Citation |
Agarwal A, Agrawal S, Talukdar D, Kaur M, Biswas S, Swaroop S, Golla R, Kandiyal B, Jana P, Tanwar S, Aggarwal A, Singh HC, Agarwal A, Mahajan M, Tiwari B, Nayak B, Goel A, Das B, Shalimar. Impact of two-session fecal microbiota transplantation on minimal hepatic encephalopathy in cirrhosis. World J Hepatol 2026; 18(4): 116153 |
| URL |
https://www.wjgnet.com/1948-5182/full/v18/i4/116153.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v18.i4.116153 |
